Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Aurantiamide

🥰Excellent
Catalog No. T5814Cas No. 58115-31-4
Alias TMC-58B

Aurantiamide has anti-cancer, anti-inflammatory and antinociceptive activities, it may suppress the growth of malignant gliomas by blocking autophagic flux.Aurantiamide has an anti-neuroinflammatory effect on LPS stimulation through its inhibition of the NF-κB, JNK and p38 pathways.

Aurantiamide

Aurantiamide

🥰Excellent
Purity: 98.88%
Catalog No. T5814Alias TMC-58BCas No. 58115-31-4
Aurantiamide has anti-cancer, anti-inflammatory and antinociceptive activities, it may suppress the growth of malignant gliomas by blocking autophagic flux.Aurantiamide has an anti-neuroinflammatory effect on LPS stimulation through its inhibition of the NF-κB, JNK and p38 pathways.
Pack SizePriceAvailabilityQuantity
1 mg$139In Stock
5 mg$347In Stock
10 mg$515In Stock
25 mg$823In Stock
50 mg$1,090In Stock
100 mg$1,490In Stock
1 mL x 10 mM (in DMSO)$493In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Aurantiamide"

Select Batch
Purity:98.88%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Aurantiamide has anti-cancer, anti-inflammatory and antinociceptive activities, it may suppress the growth of malignant gliomas by blocking autophagic flux.Aurantiamide has an anti-neuroinflammatory effect on LPS stimulation through its inhibition of the
In vitro
Aurantiamide was shown to block the activation of nuclear factor-kappa B (NF-κB) in lipopolysaccharide (LPS)-induced BV2 microglial cells by inhibiting the phosphorylation of the inhibitor kappa B-α (IκB)-α. Aurantiamide decreased the phosphorylation levels of c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinases (MAPKs).Suggested that aurantiamide has an anti-neuroinflammatory effect on LPS stimulation through its inhibition of the NF-κB, JNK and p38 pathways[1].Aurantiamide has potent anti-viral and anti-inflammatory effects on IAV-infected cells via inhibition of the NF-κB pathway. Therefore ,Aurantiamide could be a potential therapeutic agent for the treatment of influenza[2].
Cell Research
The anti-viral activity of aurantiamide against Influenza A virus (IAV) was determined using the cytopathic effect (CPE) inhibition assay.?Viruses were titrated on Madin-Darby canine kidney (MDCK) cells by plaque assays.?Ribonucleoprotein (RNP) luciferase reporter assay was further conducted to investigate the effect of aurantiamide on the activity of the viral polymerase complex.?HEK293T cells with a stably transfected NF-κB luciferase reporter plasmid were employed to examine the activity of aurantiamide on NF-κB activation.?Activation of the host signaling pathway induced by IAV infection in the absence or presence of aurantiamide was assessed by western blotting.?The effect of aurantiamide on IAV-induced expression of pro-inflammatory cytokines was measured by real-time quantitative PCR and Luminex assays[2].
AliasTMC-58B
Chemical Properties
Molecular Weight402.49
FormulaC25H26N2O3
Cas No.58115-31-4
SmilesOC[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)c1ccccc1
Relative Density.1.191 g/cm3 (Predicted)
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 50 mg/mL (124.22 mM)
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.4845 mL12.4227 mL24.8453 mL124.2267 mL
5 mM0.4969 mL2.4845 mL4.9691 mL24.8453 mL
10 mM0.2485 mL1.2423 mL2.4845 mL12.4227 mL
20 mM0.1242 mL0.6211 mL1.2423 mL6.2113 mL
50 mM0.0497 mL0.2485 mL0.4969 mL2.4845 mL
100 mM0.0248 mL0.1242 mL0.2485 mL1.2423 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Aurantiamide | purchase Aurantiamide | Aurantiamide cost | order Aurantiamide | Aurantiamide chemical structure | Aurantiamide in vitro | Aurantiamide formula | Aurantiamide molecular weight